# EDGAR Filing Document

**Accession Number:** 0001812727
**File Stem:** 0001493152-26-021123
**Filing Date:** 2026-5
**Character Count:** 94192
**Document Hash:** 81d4a61fb1eee85001151b83af54a7bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-021123.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001493152-26-021123

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20260428

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Reliance Global Group, Inc.
- **CENTRAL INDEX KEY:** 0001812727
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 463390293
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40020
- **FILM NUMBER:** 26938358

**BUSINESS ADDRESS:**
- **STREET 1:** 300 BOULEVARD OF THE AMERICAS,
- **STREET 2:** SUITE 105
- **CITY:** LAKEWOOD
- **STATE:** NJ
- **ZIP:** 08701
- **BUSINESS PHONE:** 732-780-4647

**MAIL ADDRESS:**
- **STREET 1:** 300 BOULEVARD OF THE AMERICAS,
- **STREET 2:** SUITE 105
- **CITY:** LAKEWOOD
- **STATE:** NJ
- **ZIP:** 08701

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **<u>April 28, 2026</u>**

**RELIANCE GLOBAL GROUP, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Florida** | **001-40020** | **46-3390293** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission <br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **300 Blvd. of the Americas, Suite 105<br> Lakewood, New Jersey** | **08701** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**<u>(732) 380-4600</u>**

(Registrant's Telephone Number, Including Area Code)

**<u>N/A</u>**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.086 per share | EZRA | The NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On April 30, 2026 (the "Closing Date"), Reliance Global Group, Inc. (the "Company") and certain of its affiliates entered into a series of definitive agreements (collectively, the "Transaction Documents") in connection with the formation of LifeSci Global Group LLC, a Delaware limited liability company ("LGG"), and the consummation by LGG of an initial investment in Innervate Radiopharmaceuticals LLC, a Delaware limited liability company ("Innervate"), an early-stage company focused on the development of radiopharmaceutical products and related technologies (the "Innervate Investment"). The Transaction Documents were entered into following the review and approval of the transactions by the independent and disinterested members of the Company's Board of Directors, as further described under Item 8.01 below.

 ****

***LGG Operating Agreement***

On April 29, 2026, the Company entered into the limited liability company operating agreement of LGG (the "LGG Operating Agreement"), pursuant to which the Company became the holder of approximately 51% of the membership interests in LGG. The remaining approximately 49% of the membership interests in LGG are held by LifeSci Management Group LLC, a Delaware limited liability company ("Management Group"), which is owned by Ezra Beyman (the Company's Chairman and Chief Executive Officer), Scott Korman (a member of the Company's Board of Directors), and David Turner. LGG was formed for the purpose of identifying and making investments in healthcare-related companies.

 ****

***Promissory Note***

On April 29, 2026, EZRA International Group LLC, a New Jersey limited liability company ("EIG") that is a wholly-owned subsidiary of the Company, and LGG entered into a Promissory Note (the "Promissory Note") in the maximum aggregate principal amount of $2,000,000. The Promissory Note bears interest at 7% per annum, compounded annually and accruing daily. Advances under the Promissory Note may be made by EIG to LGG from time to time at EIG's discretion. The entire outstanding principal amount and accrued interest are payable on the earlier of (i) an event of default and (ii) the fifth anniversary of the effective date of the Promissory Note (April 29, 2031), subject to extension by mutual written agreement.

 ****

***Innervate Subscription Agreement and Side Letter***

On the Closing Date, LGG entered into a Unit Subscription Agreement (the "Subscription Agreement") and a related Letter Agreement (the "Side Letter", and together with the Subscription Agreement, the "Innervate Agreements") with Innervate, pursuant to which LGG agreed to subscribe for up to 421,053 Class A units of Innervate at a purchase price of $4.75 per unit, for an aggregate purchase price of $2,000,001.75, payable in installments. Upon completion of the investment, LGG will hold a minority equity interest in Innervate. Pursuant to the Side Letter, LGG is also entitled to (i) a one-time priority distribution of $4.75 per unit out of proceeds from a sale of Innervate's Priority Review Voucher, a liquidity event or operating distributions, payable in priority to ordinary distributions and (ii) warrants to purchase additional Innervate units, issued in tranches at the rate of one warrant for every two units issued, with an aggregate cap of 210,526 warrants, a strike price of $4.75 per unit and an expiration date of October 31, 2029. The Innervate units are being issued to LGG in a private placement made by Innervate in reliance on Rule 506(b) of Regulation D under the Securities Act of 1933, as amended.

The foregoing descriptions of the Transaction Documents do not purport to be complete and are qualified in their entirety by reference to the full text of the Promissory Note, the Subscription Agreement, and the Side Letter, copies of which are filed as Exhibits 10.1, 10.2, and 10.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

The Transaction Documents have been included as exhibits to this Current Report on Form 8-K to provide investors and security holders with information regarding their terms. They are not intended to provide any other factual information about the Company, LGG, EIG, Innervate or any of their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Transaction Documents were made only for the purposes of those agreements and as of specific dates, were solely for the benefit of the parties to the applicable agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the applicable agreement instead of establishing these matters as facts. Investors and security holders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company, LGG, EIG, Innervate or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the applicable agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth under Item 1.01 of this Current Report on Form 8-K with respect to the Promissory Note is incorporated by reference into this Item 2.03. The Promissory Note has a maximum aggregate principal amount of $2,000,000, bears interest at 7% per annum (compounded annually), and matures on the fifth anniversary of its effective date (April 29, 2031). As of the Closing Date, EIG advanced $500,000 of principal under the Promissory Note. EIG may make additional advances from time to time at its discretion, up to the maximum principal amount, with each advance recorded on records maintained by EIG.

**Item 7.01 Regulation FD Disclosure.**

On April 30, 2026, the Company issued a press release announcing the matters described in Items 1.01 and 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

 ****

***Formation of LifeSci Global Group LLC***

On April 29, 2026, the Company formed LGG as a Delaware limited liability company for the purpose of identifying and making investments in healthcare-related companies, with an initial emphasis on early-stage life sciences and related technologies. The Company holds approximately 51% of the membership interests in LGG. The remaining approximately 49% of the membership interests in LGG are held by Management Group, which in turn is owned by Ezra Beyman, the Company's Chairman and Chief Executive Officer; Scott Korman, a member of the Company's Board of Directors; and David Turner, a business associate of Mr. Korman. LGG's investments are funded through loans from the Company (either directly or through its wholly-owned subsidiary EIG) to LGG.

 ****

 ****

***Related-Party Interests and Independent Director Approval***

The formation of LGG, the Promissory Note, and the Innervate Investment constitute related-party transactions within the meaning of Item 404 of Regulation S-K, in which multiple directors and executive officers of the Company have direct or indirect material interests. Specifically:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Mr. Beyman, the Company's Chairman and Chief Executive Officer, indirectly holds an equity interest in LGG through his ownership of Management Group;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Mr. Korman, a member of the Company's Board of Directors, indirectly holds an equity interest in LGG through his ownership of Management Group, and serves as the Chief Executive Officer and a member of the board of managers of Innervate, the recipient of LGG's initial investment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Mr. Turner, a business associate of Mr. Korman, indirectly holds an equity interest in LGG through his ownership of Management Group.

The transactions described in this Current Report on Form 8-K were reviewed and approved by the independent and disinterested members of the Company's Board of Directors, in accordance with the Company's policy on related-party transactions and Section 607.0832 of the Florida Business Corporation Act. Mr. Beyman and Mr. Korman recused themselves from all Board deliberations and voting regarding the transactions and did not participate in the approval thereof.

 ****

***Changes to Composition of Board Committees***

On April 28, 2026, and in connection with the related-party transactions described above and Mr. Korman's ongoing role as Chief Executive Officer and a member of the board of managers of Innervate, the Board of Directors of the Company approved the following changes to the composition of the standing committees of the Board, in each case effective as of April 28, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● **Audit Committee.** Mr. Korman was removed as a member and as Chairman of the Audit Committee. Alex Blumenfrucht was appointed as a member of the Audit Committee, and Ben Fruchtzweig was appointed as Chairman of the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● **Compensation Committee.** Mr. Korman was removed as a member of the Compensation Committee. Mr. Fruchtzweig was removed as Chairman of the Compensation Committee. Mr. Blumenfrucht was appointed as a member and as Chairman of the Compensation Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● **Nominating Committee.** Mr. Korman was removed as a member of the Nominating Committee, and Mr. Blumenfrucht was appointed as a member of the Nominating Committee.

Following the foregoing changes, each of the Audit Committee, the Compensation Committee, and the Nominating Committee is composed solely of directors whom the Board has affirmatively determined to be independent under the applicable rules of The Nasdaq Stock Market LLC and, with respect to the Audit Committee, Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Mr. Korman continues to serve as a member of the Board. Mr. Korman's departure from the committees was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Promissory Note, dated April 29, 2026, by and between EZRA International Group LLC and LifeSci Global Group LLC.](ex10-1.htm) |
| 10.2 | [Unit Subscription Agreement, dated April 30, 2026, by and between Innervate Radiopharmaceuticals LLC and LifeSci Global Group LLC.](ex10-2.htm) |
| 10.3 | [Letter Agreement (Side Letter), dated April 30, 2026, by and between Innervate Radiopharmaceuticals LLC and LifeSci Global Group LLC.](ex10-3.htm) |
| 99.1 | [Press Release, dated May 4, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Reliance Global Group, Inc.** | **Reliance Global Group, Inc.** |
| Dated: May 4, 2026 | By: | */s/ Ezra Beyman* |
|  |  | Ezra Beyman |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Maximum Principal Amount: $2,000,000 | Effective Date: April 29, 2026 |

---

FOR VALUE RECEIVED, LifeSci Global Group LLC, a Delaware limited liability company with its principal place of business located at 300 Blvd. of the Americas, Suite 105, Lakewood, New Jersey 08701 ("***Maker***"), promises to pay to EZRA International Group LLC, a New Jersey limited liability company having an address at 300 Blvd. of the Americas, Suite 105, Lakewood, New Jersey 08701 (the "***Payee***") at its offices, or such other place as may be designated in writing by the Payee, the aggregate unpaid principal amount of all Advances (as defined below) made by the Payee to the Maker from time to time hereunder, up to a maximum aggregate principal amount of $2,000,000 (the "***Maximum Principal Amount***"; the aggregate unpaid principal amount of Advances outstanding from time to time, the "***Principal Amount***"), together with interest computed on the Principal Amount from the date of each Advance at a rate set forth below, payable in lawful money of the United States of America.

This Promissory Note is executed in connection with the purchase by the Maker of certain equity interests in Innervate Radiopharmaceuticals LLC (all such interests and any proceeds thereof (the "***Collateral***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>RATE OF INTEREST</u>. This Promissory Note shall bear interest on the outstanding Principal Amount of each Advance at an annual rate of seven percent (7%), compounded annually and accruing daily from (and including) the date such Advance is made by the Payee on the basis of a three hundred sixty-five day (365) or three hundred sixty-six (366) day year, as appropriate, for the actual number of days elapsed. For the avoidance of doubt, no interest shall accrue on any portion of the Maximum Principal Amount that has not been advanced to the Maker. Following the occurrence and during the continuance of any Event of Default, as defined below, the interest rate otherwise applicable pursuant to this Section 1 shall be increased, at Payee's election, by five percent (5%) (the "***Default Rate***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>PAYMENT OF INTEREST AND PRINCIPAL</u>. The entire outstanding Principal Amount and accrued interest shall be due and payable on the earlier of (i) an Event of Default, or (ii) the fifth (5<sup>th</sup>) anniversary of the Effective Date (such date, the "***Maturity Date***"), provided, such Maturity Date may be extended by mutual agreement in writing by Maker and Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>ADVANCES</u>. From and after the Effective Date and until the Maturity Date, the Payee may, in its discretion, make one or more loan advances to the Maker (each, an "***Advance***") in such amounts and at such times as the Payee and the Maker may agree, provided that the aggregate principal amount of all Advances outstanding hereunder shall not at any time exceed the Maximum Principal Amount. Each Advance shall be evidenced by this Promissory Note and shall be recorded by the Payee on a grid maintained by the Payee (or otherwise in the Payee's books and records), which recordation shall, absent manifest error, constitute conclusive evidence of the date and amount of each Advance and of the outstanding Principal Amount; provided that any failure to make, or error in making, any such recordation shall not affect the obligations of the Maker to repay the Principal Amount, together with accrued interest thereon, in accordance with the terms hereof. Amounts repaid hereunder may not be reborrowed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>PREPAYMENT</u>. This Promissory Note may be prepaid in whole or in part at any time. Any prepayment shall first be applied to accrued interest, and then to Principal Amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>EVENTS OF DEFAULT BY THE MAKER</u>. If any of the following events ("***Events of Default***") shall occur:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Maker shall fail to make payment of interest or principal under this Promissory Note on the Maturity Date, provided such non-payment continues uncured for a period of thirty (30) days following written notice thereof to Maker;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) A petition seeking relief, or the granting of relief, under the bankruptcy laws shall be filed by or against Maker and such petition shall not be discharged or dismissed for a period of forty-five (45) days, the making of a general assignment for the benefit of creditors by Maker or any action by Maker for the purpose of effecting the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The appointment of a receiver for Maker by a court of competent jurisdiction, which appointment shall not have been vacated within a period of forty-five (45) days after the date of appointment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Maker breaches any of its covenants or agreements set forth in this Promissory Note;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Maker undergoes a merger, dissolution, liquidation or consolidation of Maker (including with or into another person), or the sale, transfer, license, lease or other disposition of (whether in one transaction or in a series of transactions) any material portion of Maker's assets (other than the Collateral); provided that, notwithstanding the foregoing, a sale, transfer or other disposition of all or any portion of the Collateral shall not constitute an Event of Default if (A) Maker provides Payee with not less than ten (10) business days' prior written notice of such proposed disposition (including reasonable detail as to the proposed terms and the expected net cash proceeds) and obtains the prior written consent of Payee to such disposition, which consent shall not be unreasonably withheld if such disposition is to an unaffiliated third party at arm's length for fair market value as reasonably determined by Payee, and (B) the net cash proceeds of such disposition are applied, concurrently with the closing thereof, to prepay the outstanding Principal Amount and accrued and unpaid interest hereunder in accordance with Section 4 (Prepayment), with any remaining proceeds released to Maker only after such application;

then, the entire outstanding Principal Amount together with all accrued interest thereon shall immediately with no further action become due and payable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Covenants</u>. Maker hereby covenants and agrees on the Effective Date and at all times thereafter, until the repayment in full of all obligations under this Promissory Note to: (a) preserve, renew and keep in full force and effect its existence; (b) pay and discharge, at or prior to maturity, all of their respective obligations and liabilities, including tax liabilities; (c) comply in all material respects with the requirements of all applicable laws and all contractual obligations; (d) give prompt written notice to Payee (i) of any litigation or governmental proceedings pending or threatened (in writing) against Maker which would in any manner call into question the validity or enforceability of this Promissory Note, or (ii) upon Maker becoming aware of the existence of any default under this Promissory Note; (e) not create, incur, assume or suffer to exist any indebtedness, except indebtedness incurred under this Promissory Note; (f) not create, incur, assume or suffer to exist any mortgage, pledge, hypothecation, collateral assignment, security deposit arrangement, encumbrance, deemed or statutory trust, security conveyance, lien (statutory or other), preference, priority, or other security agreement of any kind or nature whatsoever upon any of the Collateral, whether now owned or hereafter acquired; (g) not guaranty or otherwise become liable for any indebtedness or other obligations of any other person; (h) not sell, lease, assign, transfer or otherwise dispose of any material portion of its property or assets including without limitation the Collateral; (i) not merge, dissolve, liquidate or consolidate with or into another person, or acquire or agree to acquire by merger, consolidation, recapitalization or other business combination or otherwise, the stock, assets or business of any person; (j) not make loans to any person or make any other investment, except for investments made in furtherance of Maker's purpose under its limited liability company agreement, including the acquisition, holding and disposition of equity or other interests in Portfolio Companies (as defined in Maker's limited liability company agreement) and any activities necessary or incidental thereto; (k) not amend or otherwise modify any organizational documents of Maker (each as in effect and delivered to Payee on the Effective Date) if any such amendment or modification could materially and adversely affect the rights and interests of Payee under this Promissory Note; (l) not bring any lawsuit or litigation against Payee or its affiliates, and each of their respective employees, partners, representatives, shareholders, officers, directors, trustees, agents, advisors, family members, other representatives thereof and persons having control thereof, and each of their permitted successors and assigns; (m) not change Maker's state of formation or organization, its existence as a limited liability company or its legal name, in each case as in effect on the Effective Date; and (n) cure any breach of the foregoing within thirty (30) days of such breach.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>SECURITY INTEREST</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In order to secure payment in full under this Promissory Note, the Maker agrees to create a first priority secured pledge on the Collateral. The Collateral will rank senior to any other form of security interest on the Collateral. From time to time, the Payee may demand, and the Maker, or any of Maker's successors shall execute, such additional documents as may be reasonably necessary to maintain the Payee's Collateral and perfect Payee's security interest in the Collateral, including without limitation a UCC-1 financing statement or a stock power or other documentation requested by Payee. The Collateral shall remain fully effective in favor of the Payee until the time at which the Principal Amount and all interest accrued thereon have been fully paid hereunder, at which time the Payee shall, upon the Maker's first request, deliver to the Maker a statement signed thereby that the Collateral is null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>NOTICES</u>. All notices or other communications required or permitted hereunder shall be in writing and delivered personally, registered or certified mail, return receipt requested and postage prepaid or by private courier service with overnight delivery requested. All notices or other communications shall be deemed given or delivered and received (a) when delivered, if delivered personally, (b) two days after mailing, if mailed by registered or certified mail, return receipt requested and postage prepaid, or (c) on the next business day after delivery to a private courier service with overnight delivery requested, if delivered to a private courier service providing documented overnight service, in each case addressed as follows:

If to the Maker, to the address following such party in the first paragraph of this Promissory Note. If to the Payee, to the address following the Payee in the first paragraph of this Promissory Note or to such other address as the recipient party has specified by prior written notice to the sending party (which change of address notice will be deemed to have been given, delivered and received upon actual receipt thereof by the recipient party).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>WAIVER</u>. Maker, for itself and its legal representatives, hereby waives presentment for payment, demand, notice of nonpayment, notice of dishonor, protest of any dishonor, notice of protest and protest of this Promissory Note, and all other notices in connection with the delivery, acceptance, performance, default or enforcement of the obligations under this Promissory Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>GOVERNING LAW; DISPUTE RESOLUTION.</u> This Promissory Note will be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of laws principles. Any controversy or dispute arising out of or relating to this Promissory Note, the interpretation of any of the provisions hereof, or the action or inaction of any party hereunder shall be submitted to arbitration in New York, New York before the American Arbitration Association under its commercial arbitration rules. Any award or decision obtained from any such arbitration proceeding shall be final and binding on the parties, and judgment upon any award thus obtained may be entered in any court having jurisdiction thereof. Notwithstanding the foregoing, Payee shall be entitled to seek (i) temporary, preliminary or other injunctive relief, (ii) specific performance, and/or (iii) any action or proceeding to enforce, perfect and/or foreclose upon its rights and remedies with respect to the Collateral (including under the Uniform Commercial Code), in each case from any court of competent jurisdiction, without such action constituting a waiver of the agreement to arbitrate or a bar to arbitration. To the fullest extent permitted by law, no action at law or in equity based upon any claim arising out of or related to this Promissory Note shall be instituted in any court by either party except (a) an action to compel arbitration pursuant to this Section or (b) an action to enforce an award obtained in an arbitration proceeding in accordance with this Section or (c) an action permitted by the immediately preceding sentence. Maker shall pay any costs and expenses incurred by Payee in enforcing the terms of this Promissory Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>JURY TRIAL WAIVER</u>. MAKER AND PAYEE HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED UPON, OR RELATED TO, THE SUBJECT MATTER OF THIS PROMISSORY NOTE AND THE BUSINESS RELATIONSHIP THAT IS BEING ESTABLISHED. THIS WAIVER IS KNOWINGLY, INTENTIONALLY AND VOLUNTARILY MADE BY MAKER AND PAYEE, AND MAKER ACKNOWLEDGES THAT NEITHER PAYEE NOR ANY PERSON ACTING ON BEHALF OF PAYEE HAS MADE ANY REPRESENTATIONS OF FACT TO INDUCE THIS WAIVER OF TRIAL BY JURY OR HAS TAKEN ANY ACTIONS WHICH IN ANY WAY MODIFY OR NULLIFY ITS EFFECT. MAKER AND PAYEE ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT MAKER AND PAYEE HAVE ALREADY RELIED ON THIS WAIVER IN ENTERING INTO THIS PROMISSORY NOTE AND THAT EACH OF THEM WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS. MAKER AND PAYEE FURTHER ACKNOWLEDGE THAT THEY HAVE BEEN REPRESENTED (OR HAVE HAD THE OPPORTUNITY TO BE REPRESENTED) IN THE SIGNING OF THIS PROMISSORY NOTE AND IN THE MAKING OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>SEVERABILITY</u>. Any provision of this Promissory Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>NON-NEGOTIABLE</u>. This Promissory Note is non-negotiable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>INTEREST RATE LIMITATION</u>. If a law, which applies to this Promissory Note and which sets maximum interest charges, is finally interpreted so that the interest collected or to be collected in connection with this Promissory Note exceeds the permitted limits, then: (i) any such interest charge shall be reduced by the amount necessary to reduce the charge to the permitted limit; and (ii) any sums already collected from Maker which exceeded permitted limits will be refunded to Maker. The Payee may choose to make this refund by reducing the principal Maker owes under the Promissory Note or by making a direct payment to Maker. If a refund reduces principal, the reduction will be treated as a permitted partial payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>HEADINGS</u>. The headings of the Sections of this Promissory Note are for convenience of reference only and shall not be deemed to modify, explain, enlarge or restrict any of the provisions hereof.

[*Signature Page Follows*]

IN WITNESS WHEREOF, Maker has executed this Promissory Note as of the date first set forth above.

---

| | |
|:---|:---|
| MAKER: | MAKER: |
| LIFESCI GLOBAL GROUP LLC | LIFESCI GLOBAL GROUP LLC |
| By: | /s/ Scott Korman |
| Name: | Scott Korman |
| Title: | Member |

---

---

| | |
|:---|:---|
| APPROVED AND AGREED BY PAYEE: | APPROVED AND AGREED BY PAYEE: |
| EZRA INTERNATIONAL GROUP LLC | EZRA INTERNATIONAL GROUP LLC |
| By: | /s/ Joel Markovits |
| Name: | Joel Markovits |
| Title: | Chief Financial Officer |

---

## Exhibit 10.2

**Exhibit 10.2**

**UNIT SUBSCRIPTION AGREEMENT**

**UNIT SUBSCRIPTION AGREEMENT** (this "<u>Agreement</u>"), dated as of April 30, 2026, by and between Innervate Radiopharmaceuticals LLC (formerly known as Illumina Radiopharmaceuticals LLC), a Delaware limited liability company (the "<u>Company</u>"), and LIFESCI GLOBAL GROUP LLC (the "<u>Subscriber</u>").

**RECITAL:**

The Company desires to sell to Subscriber, and Subscriber desires to purchase from the Company, a membership interest in the Company in accordance with the terms and conditions contained herein. Capitalized terms used but not defined herein have the meanings given to them in the Company's Amended and Restated Operating Agreement, dated as of December 30, 2021, as the same may be amended from time to time, the form of which is annexed hereto (the "<u>Operating Agreement</u>").

**NOW, THEREFORE**, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. <u>Subscription for Membership Interests</u>**. Subscriber hereby subscribes for 421,053 Units in the Company (the "<u>Units</u>") in accordance with the terms and conditions contained herein and in the Operating Agreement. As full payment for and in satisfaction of this subscription, the Subscriber agrees to pay the sum of two million and one dollar and seventy five cents ($2,000,001.75) to the Company (the "<u>Subscription Price</u>") or a subscription price per Unit of $4.75. The Subscriber understands and agrees that until such subscription is accepted by the Company, the Company reserves the right to reject this subscription for any reason or no reason, in which event the Subscription Price shall be refunded to the Subscriber without deduction and this Agreement shall have no further force or effect. Attached hereto is a Capitalization Table setting forth the ownership of the Company as of February 28, 2026, which is prior to the offering of the Units and related offers of similar units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. <u>Execution of Operating Agreement</u>**. As a condition of receiving the Units, Subscriber has previously executed a counterpart signature page to the Operating Agreement. Subscriber acknowledges receipt of a copy of the Operating Agreement and that it has reviewed the Operating Agreement. Subscriber understands that the rights granted to Subscriber under the Operating Agreement are complex in nature, and have certain legal, tax and financial consequences to Subscriber. Subscriber has been advised by the Company to consult, and Subscriber has had an opportunity to consult and has consulted, to the extent Subscriber desired to do so, with Subscriber's own legal, tax and financial advisors with respect to these consequences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. <u>Representations and Warranties of the Company</u>.** The Company represents and warrants to Subscriber that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Organization</u>. The Company is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Operating Agreement</u>. Attached hereto as <u>Exhibit A</u> is a full and complete copy of the Company's Operating Agreement which sets forth the rights of the holders of membership interests in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Legality; Binding Agreement</u>. The Company has the requisite power and authority to enter into this Agreement and to issue the Units hereunder. This Agreement is and will remain the Company's valid and binding agreement, enforceable against the Company in accordance with its terms, subject, as to the enforcement of remedies, to any applicable bankruptcy, insolvency or other laws affecting the enforcement of creditors' rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. <u>Representations and Warranties of Subscriber</u>.** Subscriber hereby represents and warrants to, and agrees with, the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Binding Agreement</u>. Subscriber has all legal capacity and requisite power and authority to enter into and perform this Agreement, and this Agreement is and will remain Subscriber's valid and binding agreement, enforceable against Subscriber in accordance with its terms, subject, as to the enforcement of remedies, to any applicable bankruptcy, insolvency or other laws affecting the enforcement of creditors' rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Investment Intent</u>. Subscriber has acquired and is acquiring the Units with the intent of holding the same for investment for Subscriber's own account and without the intent or a view to participating directly or indirectly in any distribution of such Units within the meaning of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), or any applicable state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Securities Regulation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Subscriber acknowledges and agrees that the Units are being issued in reliance on an exemption from registration under the Securities Act and exemptions contained in applicable state securities laws, and that the Units cannot and will not be sold or transferred except in a transaction that is exempt under the Securities Act and applicable state securities laws or pursuant to an effective Registration Statement under the Securities Act and applicable state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Subscriber is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act (the definition of which is set forth on <u>Exhibit D</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Subscriber understands that Subscriber has no contractual right for the registration under the Securities Act of the Units and that, unless the Units are registered or an exemption from registration is available, the Units may be required to be held indefinitely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Economic Risk</u>. Subscriber is able to bear the economic risk of the loss of its entire investment in the Company. <u>Information</u>. Subscriber has received all information pertaining to an investment in the Company requested by Subscriber. Subscriber has had a reasonable opportunity to ask questions of and receive answers concerning the Company, and all such questions have been answered to Subscriber's satisfaction. Subscriber is an experienced and sophisticated investor, capable of understanding and evaluating the risks of investing in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Third Party Consents</u>. No consent of any third party is required as a condition to entering into this Agreement by Subscriber other than such consents that have been previously obtained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Broker</u>. Neither Subscriber nor any affiliate of Subscriber has engaged or dealt with any broker or finder in connection with the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>No Conflict</u>. Neither the execution and delivery by Subscriber of this Agreement, nor compliance by Subscriber with the terms and provisions hereof, will result in any breach of the terms, conditions or provisions of, or conflict with or constitute a default under, or result in the creation of any lien, charge or encumbrance upon any property or assets of, Subscriber pursuant to the terms of any indenture, mortgage, deed of trust, note, evidence of indebtedness, agreement or other instrument to which Subscriber may be party or by which it or any of its properties or assets may be bound or, to Subscriber's knowledge, violate any provision of law, or any applicable order, writ, injunction, judgment or decree of any court, or any order or other public regulation of any governmental commission, bureau or administrative agency. **<u>Risk Factors</u>**. The Subscriber understands and acknowledges that an investment in the Company involves a high degree of risk and has carefully evaluated the following risk factors in deciding to subscribe for the Units:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>No Prior Operating History, No Working Capital; Need for Substantial Additional Capital</u>. The Company was incorporated in 2019 to enter into a license agreement (the "<u>License Agreement</u>") with Ground Fluor Pharmaceuticals, Inc., a Delaware corporation ("<u>GFP</u>") for the rights to develop, manufacture commercialize and market products utilizing GFP's meta-Fluorobenzyl-Guanidine technology for the diagnosis and/or treatment of all human indications. The operations of the Company are subject to all the risks inherent in a Company whose revenues and success are dependent upon the successful development and marketing of new products. The evaluation of the Company must be considered in light of the risks, expenses and difficulties encountered by new businesses in the pharmaceutical, imaging and diagnostics industries, which is characterized by an increasing number of participants, intense competition and a high failure rate. The development and commercialization of the Company's products will require substantial resources to fund its research, development, regulatory, sales, manufacturing and other expenditures. There can be no assurance that the Company will have sufficient funds to develop its products or that it will ever achieve revenues on sales or achieve profitable operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Potential Future Dilution</u>. The Company's Board of Managers has the authority and discretion to issue additional Units and/or preferred units in the Company, with terms, rights, preferences and priorities superior to those Units offered and sold to Subscriber hereunder. The sale of such interests of the Company in the future could result in further dilution of purchasers of the Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Financial Statements and Use of Proceeds</u>. The Company's Balance Sheet as of December 31, 2025 is attached hereto as <u>Exhibit C</u>. The current follow-on offering of the Units to existing investors does not have a minimum targeted amount (the "<u>Minimum Subscription Amount</u>"). When and if the Minimum Subscription Amount has been raised, such amount will not be sufficient to cover the Company's anticipated costs and expenses necessary to bring the Company's first asset through the completion of a Phase III trial and a New Drug Application (an "<u>NDA</u>") approval with the Food and Drug Administration (the "<u>FDA</u>"). The Subscriber understands that the Company's Board of Managers may in its discretion, pursuant to the terms of the Operating Agreement, increase the aggregate fund raising and issue additional Units to additional investors to finance the Company for any additional cost of the Phase III trial and NDA application, contingency costs, additional pipeline development and commercialization activities. The Subscriber further understands that Company expects that the proceeds raised through the sale and issuance of its Units will be utilized to pay additional amounts due under the License Agreement as well as expenses of the offering and operating, research and development expenses and costs and commercialization activities. If the current offering to existing investors is successful and completely subscribed for, the Company may still require additional financing. There can be no assurance either the current offering will be successful or that any such additional financing will be obtained on acceptable terms, if at all. The failure to timely obtain sufficient additional financing will have a material adverse effect upon the Company's business, financial condition and prospects and there is no guarantee that such additional capital will be raised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>License Milestones</u>. The License Agreement provides for milestones to be achieved. In the event the Company does not meet the requirements and there isn't an agreement to extend milestone dates, GFP will have the right to terminate the License Agreement, in which event all previous license fees paid to date including will be lost and the Company will may be forced to cease operations. GFP has extended milestone deadlines in the past.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Limited Voting Rights; Control of Board of Managers</u>. The holders of Units have the right to vote on any matter for which they are entitled under the terms of the Operating Agreement. Pursuant to the Operating Agreement, the Company's Board of Managers is empowered to make all decisions regarding the Company and its operations, including, without limitation, the ability to change the name of the Company and to make any change to the Operating Agreement that does not adversely affect the Members in any material respect. Under the Operating Agreement, holders of the Units do not have the right to remove or replace the members of the Company's Board of Managers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Technology Transfer and Product Development Risk</u>. The pharmaceutical industry in general, and diagnostic product market in particular, are subject to rapid technological changes such as the possible development of new pharmaceuticals and approaches which may render the Company's licensed technology and products obsolete or require significant unanticipated investments in research and development on the part of the Company to remain competitive. There can be no assurance that the Company will be able to be successful in meeting the specific products' design challenges, such as clinical effectiveness or cost-effective production and user-friendly delivery systems. The Company's future success will depend, in part, upon its ability to keep abreast of the latest developments in the industry and to keep pace with changing customer requirements. The Company will likely experience unanticipated problems relating to product development, testing, regulatory compliance, manufacturing, marketing and competition, and our costs and expenses could exceed current estimates. The Subscriber understands that the Company cannot predict whether the Company will successfully develop and commercialize any products. There can be no assurance that the Company will not experience difficulties that could delay or prevent the successful and continued development of its products. Even if the Company is successful in developing its proposed products, it is subject to the risks that the products will be found to be ineffective or unsafe; will not receive necessary regulatory clearances; will be unable to get to market in a timely manner; will not be capable of being produced in commercial quantities at reasonable costs; will not be successfully marketed; will not be widely accepted by the medical community or that competitors will erode the Company's advantages in the diagnostic product markets or render the Company's products obsolete.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Regulatory Approval Hurdles</u>. The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of the Company's proposed products are subject to extensive regulation by the FDA in the United States and by comparable health regulatory authorities in foreign markets. In the United States, the Company is not permitted to market its proposed products without FDA approval. The process of obtaining FDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. In addition to the significant clinical testing requirements, our ability to obtain marketing approval for these products depends on obtaining the final results of required non-clinical testing, including characterization of the manufactured components of products and validation of manufacturing processes. With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. Approval of a product candidate in the U.S. or foreign markets may be delayed, limited or denied for many reasons outside of the control of the Company and any such delays in obtaining, or inability to obtain, applicable regulatory approvals would prevent the Company from commercializing its products once developed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Uncertainty of Patents and Proprietary Technology</u>. The Company's success will depend in large part on its ability to maintain the proprietary nature of its technology through a combination of patent and trade secret protection, non-disclosure agreements and licensing agreements. Though the FDA grants a seven year exclusive period to drugs approved for orphan diseases, there can be no assurance these patents will be an effective protection and that any additional patent protection sought will be obtained in the United States or elsewhere, or that any such protection, if obtained, will be effective. To the extent that trade secrets of the Company are not patentable or not patented, there can be no assurance that third parties will not develop similar or superior methods, or that such trade secrets will not be revealed upon 'reverse-engineering' of the Company's products.

Patent applications in the United States are maintained in secrecy until patents issue, and patent applications in foreign countries are maintained in secrecy for a period after filing. Publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries and the filing of related patent applications. Patents issued, and patent applications filed relating to pharmaceuticals and manufacturing of pharmaceuticals and pharmaceutical ingredients are numerous and there can be no assurance that current and potential competitors and other third parties have not filed or in the future will not file applications for or have not received or in the future will not receive, patents or obtain additional proprietary rights relating to products or processes used or proposed to be used by the Company. The Company is aware of certain patents issued to third parties that contain subject matter related to the Company's technology. The Company believes that the technologies being licensed by the Company pursuant to the License Agreement for its products do not infringe the claims of any such patents. There can be no assurance, however, that third parties will not seek to assert that the Company's products, when developed, infringe their patents or seek to expand their patent claims to cover aspects of the Company's licensed technology.

The pharmaceutical industry in general, and the diagnostic industry segment in particular, have been characterized by substantial competition and numerous patents. Any such claims, whether with or without merit, could be time-consuming and expensive to respond to and could divert the attention of the Company's technical and management personnel. The Company may be involved in litigation to defend against claims of infringement by the Company, to enforce patents issued to the Company, or to protect trade secrets of the Company. If any relevant claims of third-party patents are upheld as valid and enforceable in any litigation or administrative proceeding, the Company could be prevented from practicing the subject matter claimed in such patents or would be required to obtain licenses from the patent owners of each such patent, or to redesign its products or processes to avoid infringement. There can be no assurance that such licenses would be available or, if available, would be available on terms acceptable to the Company or that the Company would be successful in any attempt to redesign its products or processes to avoid infringement. Accordingly, an adverse determination in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent the Company from manufacturing and selling its products, which would have a material adverse effect on the Company's business, financial condition, and results of operations. The Company intends to rigorously protect and defend its intellectual property. Costly and time-consuming litigation brought by the Company may be necessary to enforce any patents issued to the Company, to protect trade secrets or know-how owned by the Company or to determine the enforceability, scope and validity of the proprietary rights of others.

There can be no assurance that additional patent protection will be obtained in the United States, the European Union, or elsewhere, or that such protection, if obtained, will be effective. Further, there can be no assurance that such patents, whether issued or pending, will not be challenged, invalidated or circumvented, or that the Company's competitors will not independently develop or patent technologies that are substantially equivalent or superior to the Company's technology. Moreover, there can be no assurance that the laws of certain foreign countries will provide sufficient protection for the Company's proprietary rights. As a result, if the Company operates on a global basis, as intended, the Company may not be able to prevent third parties from using its proprietary technology in certain foreign jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Competition</u>. The Company operates in a highly competitive industry, and the Company expects competition to increase in the future. The Company's competitors have substantially greater managerial, financial, marketing, manufacturing and/or research and development, resources than the Company. To be successful, the Company believes its products must achieve minimum levels of price, quality and performance, ease-of-use, and regulatory approval required by the marketplace. There can be no assurance that the Company's products will meet these requirements or that the Company's competitors will not also be able to meet these requirements and develop products which are comparable or superior to those of the Company or that would render the Company's technology or products obsolete or non-competitive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Hiring of Certain Key Personnel Has Not Yet Occurred; Dependence on Officers and Key Personnel</u>. The Company is highly dependent on its executive officers; currently Scott Korman, David Turner, Arnold Jacobson and Thomas Tulip. the loss of any of whom could have an adverse effect on the future operations of the Company. The Company's success is also highly dependent on its ability to attract, retain and motivate highly trained R&D and management personnel, and consultants who are capable of developing products for the Company. An inability to attract, retain and motivate personnel and consultants required for the development, maintenance and conduct of the Company's products and activities could adversely affect its business and prospects. There can be no assurance that the Company will be able to attract or retain the qualified employees it needs to be successful.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Litigation</u>. There is no pending or threatened litigation against the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Limited Transferability and Liquidity of the Units</u>. The Unit being offered hereby are being offered as a private placement of securities. There is, at present, no trading market for the Units and none is expected to exist. The Units may not be sold or transferred unless registered under the Securities Act of 1933, as amended (the "Act"), and applicable state securities laws, or unless an opinion of counsel satisfactory to the Company is obtained to the effect that an exemption from registration is available and such transfer is approved by the Board of Managers, and no registration under the Act is contemplated for the foreseeable future. As a result, the purchase of the Units should be considered a long-term investment. the Company MAY NEVER file a registration statement to register THE UNITS, AND EVEN IF IT DOES SO, THERE CAN BE NO ASSURANCE that such registration statement will become effective, or that once effective, such effectiveness will be maintained. Because of these restrictions and the absence of a trading market for the Units, Subscriber may be unable to liquidate its investment even though financial circumstances would make liquidation desirable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Absence of Dividends</u>. The Company does not presently anticipate authorizing the payment of any distributions on the Units in the foreseeable future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>Arbitrary Offering Price</u>. The offering price of the Units have been arbitrarily determined by the Company, and such offering price are not necessarily related to the Company's asset value, net worth, projected future value, results of operations, financial condition or any other established criteria of value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. <u>Notices</u>.** Any notice or communication permitted or required by this Agreement shall be in writing and shall be deemed to have been duly and properly given or served for any purpose only if delivered personally with receipt acknowledged or sent by registered or certified mail, return receipt requested, postage and charges prepaid, by overnight courier, or by confirmed email transmission.

If to the Subscriber:

LIFESCI GLOBAL GROUP LLC

300 Boulevard of the Americas

Lakewood, NJ 08701

If to Company:

Innervate Radiopharmaceuticals LLC

175 Elm Road

Englewood, New Jersey 07631

Attention: Scott Korman

With a Copy to:

Duane Morris LLP

201 S. Biscayne Boulevard, Suite 3400Miami, FL 33131-4325

Attn: Stephen Rutenberg

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. <u>General</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No waiver by the Company of any breach of this Agreement will be a waiver of any preceding or subsequent breach. No waiver by the Company of any right under this Agreement will be construed as a waiver of any other right. The Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement may not be assigned by Subscriber. This Agreement shall be binding upon and inure to the benefit of Subscriber and the Company and the Company's successors and assigns. Successors of the Company shall include, without limitation, any entity or entities acquiring, directly or indirectly, all or substantially all of the assets of the Company, whether by merger, consolidation, purchase, lease or otherwise, and a successor shall thereafter be deemed the "<u>Company</u>" for the purposes hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The captions and Section headings used in this Agreement are for convenience of reference only and will not affect the construction or interpretation of this Agreement or any of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The validity and construction of this Agreement or any of its provisions will be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflicts of law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) This Agreement may be executed by pdf or other electronic signature and in counterparts, each of which will be deemed to be an original hereof, but all of which together will constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Parties agree that any principle of construction or rule of law that provides that an agreement shall be construed against the drafter of the agreement in the event of any inconsistency or ambiguity in such agreement shall not apply to the terms and conditions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) This Agreement, together with the Operating Agreement, constitutes the sole and entire agreement and understanding between the parties hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and understandings of every kind and nature between them as to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) This Agreement is intended for the sole and exclusive benefit of the parties hereto and their respective successors and permitted assigns, and no other person or entity will have any right to rely on this Agreement or to claim or derive any benefit therefrom absent the express written consent of the party to be charged with such reliance or benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Subscriber has read this Agreement carefully and fully understands its terms.

**<u>THE REMAINDER OF THIS PAGE IS BLANK</u>**

IN WITNESS WHEREOF, the parties have executed and delivered, or caused to be executed and delivered, this Membership Interest Subscription Agreement as of the date first written above.

---

| | |
|:---|:---|
| **COMPANY:** | **COMPANY:** |
| **INNERVATE RADIOPHARMACEUTICALS LLC** | **INNERVATE RADIOPHARMACEUTICALS LLC** |
| By: | /s/ Scott Korman |
| Name: | Scott Korman |
| Title: | CEO |
| **SUBSCRIBER:** | **SUBSCRIBER:** |
| **LIFESCI GLOBAL GROUP LLC** | **LIFESCI GLOBAL GROUP LLC** |
| By: | /s/ Ezra Beyman |
| Name: | Ezra Beyman |
| Address: | LIFESCI GLOBAL GROUP LLC |
|  | 300 Boulevard of the Americas |
|  | Lakewood, NJ 08701 |
| SS# or EIN #: | SS# or EIN #: |

---

**EXHIBIT A**

**<u>AMENDED AND RESTATED OPERATING AGREEMENT</u>**

[ATTACHED]

**EXHIBIT B**

**Capitalization Table**

![](ex10-2_001.jpg)

**EXHIBIT C**

![](ex10-2_002.jpg)

**EXHIBIT D**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Accredited investor. Accredited investor* shall mean any person who comes within any of the following categories, or who the issuer reasonably believes comes within any of the following categories, at the time of the sale of the securities to that person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Any bank as defined in section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any insurance company as defined in section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Any organization described in section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Any director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) Any natural person whose individual net worth, or joint net worth with that person's spouse, exceeds $1,000,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Except as provided in paragraph (a)(5)(ii) of this section, for purposes of calculating net worth under this paragraph (a)(5):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) The person's primary residence shall not be included as an asset;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Indebtedness that is secured by the person's primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) Indebtedness that is secured by the person's primary residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be included as a liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Paragraph (a)(5)(i) of this section will not apply to any calculation of a person's net worth made in connection with a purchase of securities in accordance with a right to purchase such securities, provided that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Such right was held by the person on July 20, 2010;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) The person qualified as an accredited investor on the basis of net worth at the time the person acquired such right; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) The person held securities of the same issuer, other than such right, on July 20, 2010.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in §230.506(b)(2)(ii); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) Any entity in which all of the equity owners are accredited investors.

## Exhibit 10.3

**Exhibit 10.3**

**Innervate Radiopharmaceuticals LLC<br> 175 Elm Road**

**Englewood, New Jersey 07631**

LIFESCI GLOBAL GROUP LLC

300 Boulevard of the Americas

Lakewood, NJ 08701

April 30, 2026

**RE: <u>CERTAIN PAYMENTS UPON TRIGGERING EVENTS AND WARRANTS ISSUANCE AND PAYMENT SCHEDULE</u>**

In connection with your execution of a subscription agreement to purchase certain units of Innervate Radiopharmaceuticals LLC (the "<u>Company</u>"), dated on or about the date hereof (such agreement, the "<u>Subscription Agreement</u>") by and between you and the Company, pursuant to this letter agreement (the "<u>Letter Agreement</u>") agree to make certain accommodations which are not specifically contemplated by the Subscription Agreement but which are consistent with the parties' intent and necessary to consummate the transactions contemplated under the Subscription Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Subscription Agreement.

The parties hereby acknowledge and agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. It is the Company's current intention to, promptly following the Company's sale of a Priority Review Voucher ("<u>PRV</u>") to issue a distribution to all Members promptly following such PRV Sale (such distribution, the "<u>PRV Dividend</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Milestone Payment</u>. In connection with your continued ownership of the Units pursuant to the Subscription Agreement dated April 30, 2026 to: sale of the Priority Review Voucher, a liquidity event resulting in a distribution to shareholders, a distribution(s) to shareholders resulting from profits generated by operations, the Company will pay to you a one-time distribution of $4.75 per Unit (the "Preferred Payment"). The Preferred Payment will be made prior to any distribution to holders of ordinary units. After the Preferred Payment, these units will be treated as ordinary units and receive all ordinary distributions and have no additional preferred payments. The Preferred Payment will be made following approval by the Company's Board of Directors that the Preferred Payment will not materially impede the Company's ability to continue as a going concern (and if such determination cannot be made, the payment shall be made as soon as practicable following such determination).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Warrants</u>. Concurrent with each issuance of Units pursuant to the payment schedule set forth herein, the Company shall issue to you Warrants to purchase Units equal to one warrant for each two Units issued in such tranche. By way of example, upon the initial payment of $500,000 and the corresponding issuance of 105,263 Units, the Company shall concurrently issue 52,631 Warrants. The aggregate number of Warrants issuable hereunder shall not exceed 210,526, corresponding to the maximum 421,053 Units issuable under the Subscription Agreement dated April 30, 2026. The Warrants will have a strike price of $4.75 and expire October 31, 2029. In the event of a liquidity event in excess of $4.75 per Unit you will have the ability to exercise the warrants on a cashless basis (you can apply $4.75 per unit of the distribution to the exercise of the warrants). For the avoidance of doubt, this Letter Agreement shall constitute the warrant instrument evidencing the Warrants described herein, and no separate warrant certificate or agreement shall be required to give effect to the rights granted hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Payment Schedule:</u>

● $500,000 upon execution of the subscription agreement

● $150,000 per month for ten months commencing July 1, 2026 and the first of each month until and including April 2027

● Units will be issued when funds are received by the Company.

For the avoidance of doubt, you acknowledge and agree that there is no guaranty that the Company will receive a PRV, nor that the Company will choose to sell a PRV, if received, nor the timing of such a sale. Only the Units purchased pursuant to the Subscription Agreement dated April 30., 2026 will be subject to the Preferred Payment.

Except as specifically modified hereby, the Subscription Agreement shall otherwise remain in full force and effect, and the parties hereto hereby ratify and confirm the same, and nothing contained herein shall otherwise be deemed or interpreted to change the terms and conditions of the Subscription Agreement. This Letter Agreement and the Company's Operating Agreement, together with the Subscription Agreement, contains the parties' entire agreement with respect to the subject matter hereof. This Letter Agreement is governed by, and subject to, the laws of the State of Delaware (without giving effect to its conflict of law provisions).

The parties hereto shall keep the fact and the terms of this Letter Agreement confidential, except as a party may be compelled by law or as required by applicable securities laws, stock exchange rules or regulations, or the disclosure obligations of any party that is a reporting company under the Securities Exchange Act of 1934 to disclose the terms of this Letter Agreement or to enforce the terms hereof.

This Letter Agreement may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which will be one and the same document. Facsimiles and electronic copies in portable document format ("<u>PDF</u>") containing original signatures shall be deemed for all purposes to be originally signed copies of the documents that are the subject of such facsimiles or PDF versions.

\* \* \*

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| INNERVATE RADIOPHARMACEUTICALS LLC | INNERVATE RADIOPHARMACEUTICALS LLC |
| By: | /s/ Scott Korman |
| Name: | Scott Korman |
| Title: | CEO |
| **Acknowledged by Investor:** | **Acknowledged by Investor:** |
| /s/ Ezra Beyman | /s/ Ezra Beyman |

---

[Signature Page to Side Letter]

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Reliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA's Biotech Division**

 

*Transaction Expands EZRA International Group's Biotech Division, LifeSci Global, Into Late-Stage Radiopharmaceutical Imaging*

 

*Initial Neuroblastoma Opportunity of Approximately $250 Million, with Additional Potential Billion-Dollar Expansion Markets and Priority Review Voucher Upside*

**LAKEWOOD, N.J.**, May 4, 2026 — **Reliance Global Group, Inc. (Nasdaq: EZRA)** ("we," "us," "our," the "Company" or "Reliance") today announced that LifeSci Global Group LLC ("LifeSci Global"), the biotech arm of EZRA International Group, has completed a strategic investment in Innervate Radiopharmaceuticals, a developer of positron emission tomography (PET) imaging and therapeutic radiopharmaceuticals focused initially on neuroblastoma and broader future applications in cardiovascular and neurodegenerative disease. This investment reflects an initial capital deployment within a broader strategy to build exposure to high-growth healthcare platforms through disciplined, staged allocation over time.

The transaction gives Reliance entry into a late-stage radiopharmaceutical platform targeting a serious unmet need in pediatric oncology, with additional expansion opportunities in cardiovascular and neurodegenerative disease and the potential for a valuable Priority Review Voucher pathway. Reliance believes the investment represents a compelling opportunity to participate in a differentiated healthcare platform with meaningful near-term upside and substantially larger long-term expansion potential.

As part of the transaction, LifeSci Global is set to acquire 421,053 shares of Innervate Radiopharmaceuticals at $4.75 per share, for a total investment of approximately $2.0 million of which $500,000 was funded at closing. LifeSci Global also holds the unilateral right to accelerate funding.

Innervate's lead asset, 18F-mFBG, is being developed as a next-generation PET imaging agent for neuroblastoma, a rare and serious pediatric cancer arising from neural crest cells, most commonly in young children. Compared with the current standard of care, 123I-mIBG SPECT imaging, Innervate's 18F-mFBG PET imaging agent is designed to provide higher-resolution images, faster scan times and improved lesion identification, with the potential to enhance diagnostic confidence, support better-informed patient management and improve the overall patient experience. Innervate's neuroblastoma program has involved leading institutions in pediatric oncology and nuclear imaging, including Memorial Sloan Kettering Cancer Center and the NANT network. Reliance believes this supports the platform's strategic significance and clinical relevance.

"We believe this is exactly the type of transformative opportunity EZRA International Group was built to pursue," said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. "Innervate represents what we view as a compelling entry into one of the fastest growing and most strategically active segments in healthcare. It combines a differentiated late-stage oncology opportunity, a potentially significant Priority Review Voucher pathway, and what we believe may be a highly expandable platform with applications that extend well beyond the initial indication."

Mr. Beyman continued, "For Reliance shareholders, we believe this transaction creates exposure to a differentiated late-stage healthcare platform with meaningful near-term upside and substantially larger long-term expansion potential. Neuroblastoma alone represents a meaningful initial opportunity, but what makes this especially compelling is the broader platform potential in cardiovascular and neurodegenerative disease markets that management believes could each exceed $1 billion. We believe this investment reflects the continued execution of our strategy to build long-term shareholder value through targeted ownership in high-upside technology and innovation-driven businesses." This approach reflects the Company's broader strategy of identifying differentiated platforms early and building exposure through disciplined capital allocation over time.

Innervate's 18F-mFBG is intended to help identify areas in the body where cancer may be present by targeting the norepinephrine transporter (NET). Compared with the current standard of care, 123I-mIBG SPECT imaging, PET-based imaging has the potential to offer higher resolution, faster scan times, improved lesion detection, dramatically improved patient experience and greater diagnostic reliability.

Reliance believes Innervate offers a rare combination of a meaningful near-term oncology opportunity and substantially larger follow-on expansion paths. The neuroblastoma market alone represents an estimated annual global revenue opportunity of approximately $250 million, while future cardiovascular and neurodegenerative applications may each address markets exceeding $1 billion. More broadly, PET imaging and radiopharmaceuticals are among the fastest-growing segments in radiology, with annual U.S. sales exceeding $2 billion and global sales exceeding $5 billion, supported by growing clinical adoption, meaningful commercial demand, and robust M&A and strategic activity across the sector. There can be no assurance that Innervate's products will receive regulatory approval or achieve commercial success, or that any of the market opportunities described herein will be realized. The investment is structured as a staged capital deployment over time, designed to provide continued exposure to the platform as development progresses.

Moshe Fishman, Senior Vice President of Strategic Ventures at Reliance Global Group, said, "We believe Innervate is a particularly attractive fit for EZRA's biotech division because it combines differentiated science, late-stage positioning and significant strategic optionality. The lead neuroblastoma program addresses an area of urgent medical need, while the broader platform may open the door to substantially larger commercial opportunities over time. In our view, this is not simply an investment in a single asset. It is an investment in a platform that we believe may support multiple future value inflection points."

Mr. Fishman added, "What stands out to us is the asymmetry of the opportunity. The initial neuroblastoma program appears meaningful on its own, but the additional upside from platform expansion, potential strategic interest and the possibility of a Priority Review Voucher, if ultimately awarded in connection with a future approval, could materially enhance the overall value proposition."

Innervate has indicated that its lead neuroblastoma program includes a pivotal efficacy and safety study and is advancing toward regulatory submission-related activities. Reliance believes the program's development timeline may present important future milestone opportunities, including potential clinical and regulatory inflection points. Innervate also anticipates the possibility of receiving a Rare Pediatric Disease Priority Review Voucher in connection with a future approval, which, if awarded, could represent an additional monetizable asset. There can be no assurance that any such voucher will be received or monetized. The Company expects continued progress across the coming quarters, with potential updates on clinical advancement and regulatory pathway activities.

The investment was made through LifeSci Global, a majority-owned subsidiary of the Company. The investment was reviewed and approved by the independent and disinterested members of the Company's Board of Directors. Interested directors recused themselves from all Board and committee deliberations regarding the transaction.

Scott Korman, a member of the Company's Board of Directors, serves as the Chief Executive Officer of Innervate and holds an equity interest in LifeSci Global. Ezra Beyman, the Company's Chairman and Chief Executive Officer, also holds an equity interest in LifeSci Global.

Reliance believes this transaction further validates EZRA International Group's broader strategy of identifying, acquiring and supporting ownership positions in innovative, high-growth businesses where disciplined capital allocation and active strategic involvement can unlock meaningful long-term shareholder value. With this investment, Reliance expands EZRA International Group into radiopharmaceuticals and advanced medical imaging, as part of its broader strategy of disciplined capital allocation across high-growth technology and life sciences platforms,

**About Reliance Global Group, Inc.**

Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer leveraging artificial intelligence (AI) and cloud-based technologies to transform and improve efficiencies in the insurance agency and brokerage industry. The Company's business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with a full suite of business development tools, enabling them to compete effectively with large-scale national insurance agencies while reducing back-office costs and burden. The Company's business-to-consumer platform, 5minuteinsure.com, uses AI and data mining to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail brick-and-mortar insurance agencies, which are leaders and pioneers in their respective regions throughout the United States and offer a wide variety of insurance products.

In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology and life sciences companies. EZRA International Group is designed to complement Reliance's core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.

Further information about the Company can be found at https://www.relianceglobalgroup.com.

**Forward-Looking Statements**

Forward-looking statements in this press release include, without limitation, statements regarding: the Company's investment in Innervate Radiopharmaceuticals through LifeSci Global Group LLC; the development, regulatory pathway, clinical progress, commercialization and market potential of Innervate's product candidates, including 18F-mFBG; the potential for Innervate to receive a Rare Pediatric Disease Priority Review Voucher and the potential value thereof; the estimated size and growth of the neuroblastoma, cardiovascular, neurodegenerative and broader radiopharmaceutical markets; the Company's strategy of identifying, acquiring and supporting ownership positions in innovative, high-growth businesses through EZRA International Group; and the expected strategic, operational and financial benefits of the Company's investments.

These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, without limitation: risks related to the development, regulatory review, clinical testing, approval, commercialization and market adoption of Innervate's product candidates, including the risk that Innervate's products do not receive regulatory approval or do not achieve commercial success; the risk that Innervate does not receive a Rare Pediatric Disease Priority Review Voucher or that any such voucher is not monetized for the amounts historically achieved by other vouchers; the risk that the estimated market opportunities described herein do not materialize or are smaller than anticipated; integration, execution and scaling challenges associated with supporting an early-stage technology company; the risk that anticipated synergies or strategic benefits are not realized on expected timelines or at all; intellectual property, cybersecurity, regulatory and data protection risks; the Company's ability to access capital on acceptable terms or at all; and general economic, market and interest rate conditions.

Such risks and uncertainties also include geopolitical risks, including the ongoing and evolving conflict involving Israel and Iran, which may result in regional instability, military activity, cyberattacks, disruptions to critical infrastructure, supply chains or communications networks or workforce disruptions. The extent, duration, and impact of such conditions remain uncertain and could materially adversely affect the Company's investments and operations.

Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, when filed, and in the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

**Contact:**

Crescendo Communications, LLC

Tel : +1 (212) 671-1020

Email : EZRA@crescendo-ir.com